Abstract: Product for the treatment of household pets as having need of a therapeutic treatment, characterised in that it comprises, in separate form and intended to be mixed: a non-foaming base suited to constituting a galenic form for topical application and/or dermatological treatment, and a concentrated preparation of at least one component with reduced biological activity and suited to acquiring a maximum biological activity in relation to the desired treatment, under the effect of an appropriate change to the pH, advantageously to pH 6-7, whereas said at least one activable component with reduced biological activity is itself premixed with at least one foaming agent and as an option at least one emulsifier in said concentrated preparation, and whereas the pH of said concentrated preparation is either less than around 5 or more than 8, with as an option adjustment to this value by means of an appropriate buffer.
Abstract: A pharmaceutical combination comprising at least a triptan and the trimebutine compound [hydrogenated maleate of 2-dimethyl-amino-2-phenylbutyl-3,4,5-trimetoxybenzoate] and an anti-inflammatory or simple analgesic for the treatment of attacks of migraine and other headaches is provided. More particularly, the present invention discloses a pharmaceutical combination comprising triptan and trimebutine for the treatment of migraine attacks. The present invention further discloses blisters and packs containing said pharmaceutical combinations.
Abstract: A biocompatible stent with a fluoride-containing hydrophilic water insoluble crosslinked resin layer. A therapeutic substance-containing layer may also be included. A method of making a biocompatible stent.
Abstract: A method for accelerating the process of removing ethanol from the blood through the use of certain additives that accelerate the metabolic oxidation of ethanol, and others which in addition act as catalysts or “pseudo” enzymes for the oxidation. These additives include multivalent transition metal ions, as well as complexes thereof, and NAD+ which enhance the oxidation reaction. The method described can act as a sobriety inducer and/or as an effective palliative for the unpleasant effects of overuse of ethanol.
Abstract: Preeclampsia and intrauterine growth restriction in a pregnant female mammal are prevented or decreased in severity by administering thereto a combination of a vitamin compound containing B1, Folic Acid (or active form 5-Methyl-Tetrahydrofolate i.e.; Metafolin®), B 6 (Pyridoxine or active form Pyridoxine 5-Phosphate P5P), B 12, Ascorbic Acid, Selenium, Zinc, Co-enzyme Q 10 and N-Acytyl Cysteine, Lycopene, optionally in further combination with Melatonin and/or Vitamin E or/and ASA 81 mg both of later, are cyclooxygenase inhibitors, a PGI.sub.2-mimetic, a thromboxane (TXA.sub.2) inhibitor, a compound possessing TXA.sub.2-agonistic and TXA.sub.2-inhibiting properties, a compound possessing TXA.sub.2-antagonistic and PGI.sub.2-mimetic activities, and a TXA.sub.2 antagonist.
Type:
Application
Filed:
October 23, 2006
Publication date:
October 4, 2007
Inventors:
Michael V. Muench, Lori L. Muench, Steven M. Feld
Abstract: An implantable drug delivery system uses a hydrophobic compound as an outer layer or barrier for retarding release of water soluble drugs from the implantable system. The system includes an inner portion of a water soluble drug in a drug matrix material which stabilizes the drug. An outer portion of the drug delivery system separates the inner portion from a surrounding environment. The outer portion retards the release of the water soluble drug from the inner portion. The outer portion includes a hydrophobic non-polymer compound and a binder. The hydrophobic compound can be another drug which can be delivered at an entirely different release kinetic from the water soluble drug and for treatment of the same or a different condition. When the drug delivery system is implanted in a body the outer portion retards the release of the water soluble drug by controlling fluid passing from the body into the inner portion and by controlling passage of the water soluble drug from the inner portion into the body.
Type:
Application
Filed:
January 24, 2007
Publication date:
July 26, 2007
Applicant:
Conor Medsystems, Inc.
Inventors:
Thai Minh Nguyen, Theodore L. Parker, John F. Shanley
Abstract: A method of treating a non-human dermatological disorder, wherein the method comprises topically administering to a non-human dermatological disorder a therapeutically effective amount of a topical composition containing: (1) an active component comprising at least one salicylate derivative; and (2) at least one pharmaceutically acceptable solubilizer.
Abstract: The present invention relates to a preparation suitable for the prevention and/or treatment of vascular disorders, comprising the following fractions: fraction a) consisting of long chain polyunsaturated fatty acids; fraction b) consisting of phospholipids, which fraction contains at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine. fraction c) consisting of compounds which are a factor in methionine metabolism, which fraction contains at least one member selected from the group consisting of folic acid, vitamin B12, vitamin B6, magnesium and zinc.
Type:
Grant
Filed:
November 2, 2000
Date of Patent:
June 5, 2007
Assignee:
N.V. Nutricia
Inventors:
Amanda Johanne Kiliaan, Robert Johan Joseph Hageman
Abstract: The present invention relates to a method for the prevention and/or treatment of vascular disorders and/or secondary disorders associated therewith, such as depression. The method according to the invention comprises the oral administration of a preparation which contains at least the following fractions: a) long chain polyunsaturated fatty acids; b) at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine and c) one or more compounds which are a factor in methionine metabolism, which compounds are selected from the group consisting of folate, vitamin B12, vitamin B6, magnesium and zinc or equivalents thereof. The invention also relates to a preparation for oral dosage comprising: at least 120 mg of long chain polyunsaturated fatty acids; at least 200 mg phospholipids; at least 200 ?g folate; and at least 0.1 mg hypericin and/or at least 100 mg extract of Withania somnifera.
Type:
Grant
Filed:
July 9, 2001
Date of Patent:
April 24, 2007
Assignee:
N.V. Nutricia
Inventors:
Amanda Johanne Kiliaan, Robert Johan Joseph Hageman
Abstract: Human papillomavirus (HPV) protein expression is downregulated in patients infected with HPV by administration of PPAR? ligand, selective inhibitor of cyclooxygenase-2 (COX-2), diaryl heterocycle, inhibitor of HPV protein from a natural source and/or certain non-steroidal anti-inflammatory drugs.
Type:
Grant
Filed:
March 14, 2002
Date of Patent:
February 27, 2007
Assignee:
Cornell Research Foundation, Inc.
Inventors:
Andrew J. Dannenberg, Kotha Subbaramaiah
Abstract: The present invention provides a topical formulation containing NSAID, particularly diclofenac. The topical formulation is particularly useful for alleviating pain/inflammation associated with infection caused by herpes virus, especially herpes simplex virus (HSV) and varicella-zoster virus (VZV). Similar relief can be achieved where diclofenac is replaced with another non-steroidal anti-inflammatory drug (NSAID), which includes, without limitation, etodolac, ketorolac, bromfenac, diflunisal, ibuprofen, fenoprofen, ketoprofen, naproxen, suprofen, meclofenamate, mefenamic acid, piroxicam, meloxicam, indomethacin, sulindac, phenylbutazone, oxyphenbutazone, and tolmetin. The topical formulation is further characterized by its fast relief on pain and/or inflammation associated with infection caused by herpes virus, i.e., a complete relief in no more than seven (7) days after the application of the topical formulation on skins of patients.
Abstract: This invention pertains to therapeutic antibacterial/antifungal-wound healing compositions comprising a therapeutically effective amount of antibacterial agents and/or antifungal agents and/or wound healing composition alone. In one embodiment, the wound healing composition comprises (a) zinc oxide; (b) calcium channel blocker, and (c) fat-soluble vitamins admixed with antibacterial and antifungal agents. The therapeutic antibacterial/antifungal-wound healing compositions may be utilized in a wide variety of pharmaceutical products and administered orally or topically.
Abstract: Use of organic compounds containing the —ONO2 function, or inorganic compound containing the —NO group or compositions comprising said compounds to reduce the toxicity caused by drugs to the gastrointestinal and/or renal apparatus, said compounds being characterized in that they are nitric oxide NO donors i.e., when they are put into contact in vitro with cells of the vasal endothelium or platelets.
Abstract: The present invention relates to novel ophthalmic pharmaceutical compositions comprising an inflammation-treating amount of a 4-aminoquinoline compound, derivative, isomers, or chemical salts, and methods for using these compositions for the treatment of ocular inflammatory conditions by topical administration directly to the eye.
Abstract: A method for assessing aspirin resistance and relative risk of a cardiovascular event in a patient taking aspirin is provided. The concentration of 11-dehydro-thromboxane B2 in a urine sample is measured and compared to a set of standardized quartile concentrations. A concentration of urinary 11-dehydro-thromboxane B2 that falls within the second, third, or fourth quartile is indicative of aspirin resistance and an elevated risk of a recurrent cardiovascular event.
Type:
Grant
Filed:
September 24, 2003
Date of Patent:
July 25, 2006
Assignee:
McMaster University
Inventors:
Salim Yusuf, Jack Hirsh, John Eikelboom
Abstract: This invention provides novel methods for improving plant quality and yield in the presence of pathogens. The method increases the levels of pathogenesis-related proteins, such as PR1, phenylalanine ammonia lyase, or plant cell wall proteins such as hydroxyproline-rich glycoproteins, in a plant by contacting the plant with a plant systemic inducer and a reactive oxygen species wherein the amount of the reactive oxygen species is sufficient to increase the amount of the pathogenesis-related protein above the level induced by the plant systemic inducer in the absence of the reactive oxygen species. A preferred reactive oxygen species is peracetic acid; a preferred plant systemic inducer is salicylic acid.
Abstract: A substantially anhydrous stable ointment containing Aspirin which is characterized in using gelation hydrocarbon and/or vaseline as a base. The ointment is superior in stability and can be stored for a long term.
Abstract: The invention concerns a method of conserving biological prostheses, wherein the method includes the following steps: (a) treating biological prostheses with a solution which contains a mixture of epoxide compounds which are at least in part of different lengths; (b) treating the biological prosthesis treated in accordance with step (a) with an antithrombotic-bearing solution; and (c) possibly storing the prosthesis treated in accordance with step (b) in a sterilising solution. The invention further concerns a biological prosthesis produced in accordance with the method of the invention and a conserving agent.
Type:
Grant
Filed:
December 3, 2001
Date of Patent:
March 21, 2006
Inventors:
Leonid Barbarash, Irina Jouravleva, Svetlana Novikova
Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.
Type:
Grant
Filed:
February 3, 2003
Date of Patent:
March 14, 2006
Assignee:
Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda
Inventors:
Werner Haas, Carlos Romao, Beatriz Roya, Ana Cristina Fernandes, Isabel Goncalves
Abstract: A kit and method for treating migraine headaches comprising the preparing of an oral composition containing at least two bags of black pekoe tea brewed in approximately three ounces of boiling water for ten to thirty seconds. After brewing, the bags of tea are removed and two 325 mg aspirin tablets, one to two teaspoonfuls or tablets of apple cider vinegar, and one to three teaspoonfuls of honey are mixed into the brewed tea. The entire hot and concentrated composition is then cooled over ice so that a person suffering from a migraine headache may quickly drink it.
Abstract: This invention relates to a method and compositions for the treatment and prevention of disorders associated with endothelial dysfunction consisting of anti-inflammatory agents and dietary supplements.
Abstract: The present invention relates, in general, to a method of preventing or delaying the onset of Alzheimer's disease and related neurodegenerative disorders. The invention also relates to a method of treating Alzheimer's disease and related neurodegenerative disorders so as to ameliorate the further progress of symptoms. The methods involve the administration of a non-steroidal anti-inflammatory agent and/or a histamine H2 receptor blocking agent. According to indication, the present method can be applied to individuals who are currently asymptomatic but at risk of developing Alzheimer's disease, to individuals who have mild cognitive symptoms that may either denote an incipient prodrome of Alzheimer's disease or represent early symptoms (prodromal stage), or to individuals who have a clinical diagnosis of Alzheimer's disease.
Type:
Grant
Filed:
April 28, 1999
Date of Patent:
March 15, 2005
Assignee:
Duke University
Inventors:
John C. S. Breitner, Kathleen A. Welsh-Bohmer
Abstract: Hairy hoof warts in animals are treated by topically administering an effective amount of a composition of aspirin or other compound or derivative of salicylic acid that preferably contains at least 50% by weight and more preferably between about 75% and 100% by weight aspirin or other compound or derivative of salicylic acid. A preferred composition includes aspirin, hydrated lime, sodium bentonite, and chalk or iron oxide.
Abstract: Disclosed are anti-viral compositions containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients), and a pharmaceutical carrier. Also disclosed are methods of treating lesionous symptoms of a viral infection involving applying an effective amount of the anti-viral composition to the lesions.
Abstract: Pharmaceutical uses of glycine betaine, such as for the treatment of thromboses not induced by hyperhomocystenemia or homocystinuria, of blood disorders, such as blood coagulation, thrombi formation.
Abstract: The invention relates to an immediate release tablet capable of being chewed or disintegrated in the oral cavity, which comprises a pharmaceutically active ingredient having an optional tastemasking coating, and a matrix comprising hydroxyalkylcellulose having a weight average molecular weight of from about 60,000 to about 5,000,000. The tablet possesses exceptionally good mouthfeel and stability.
Abstract: Method for treating dermatosis and pruritus due to hemodialysis by applying to a patient suffering from said diseases due to hemodialysis the external preparation containing Aspirin as an active ingredient.
Abstract: The present inventors revealed that non-steroidal anti-inflammatory drugs and muscle relaxants suppressed the expression of genes carried on viral vectors. These agents also suppressed viral vector cytotoxicity. The present invention provides a method for regulating the expression of genes carried on viruses by using non-steroidal anti-inflammatory drugs and/or muscle relaxants. The effect of these agents is reversible, and viral vector gene expression and cytotoxicity increased after termination of agent administration. The agents of the present invention are useful for regulating the expression of viral and therapeutic genes, and for suppressing viral vector cytotoxicity in gene therapy using viral vectors.
Abstract: A transdermal delivery composition comprising at least one skin permeation enhancer and at least one active ingredient or pharmaceutically acceptable salt thereof. The combination of components in the composition of the present invention enhances transdermal absorption of the active ingredient. This abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.
Abstract: A composition for accelerating the disposal of ethanol from bodily fluid. Certain additives can accelerate the metabolic oxidation of ethanol, and others in addition act as catalysts or “pseudo” enzymes for the oxidation. Additives include the oxidant Nicotinamide Adenine Dinucleotide and a variety of other additives such as transition metal ions and complexes thereof which favor the oxidation reaction. The compositions described can act as a sobriety inducer and/or as an effective palliative for the unpleasant effects of overuse of ethanol.
Type:
Grant
Filed:
June 7, 2001
Date of Patent:
December 21, 2004
Inventors:
Ward Beryl Bowen, Jr., Daniel Salman Daniel
Abstract: Methods are provided for protecting an individual from adverse long-term effects of neuroinflammation. Inflammatory blockade maintains neurogenesis capability after cranial irradiation by reducing the negative effects of activated microglia on neural precursor cells. These findings have broad implications for a variety of diseases of cognition, involving neuroinflammation and precursor cell dysfunction.
Abstract: Embodiments of the invention generally provide pharmaceutical drug compositions, methods of preparing oral drug compositions, such as extended release dosage compositions, and methods for treating infection. More particularly, the invention relates to formulations containing a drug and a carrier material. In one aspect, the invention provides a pharmaceutical formulation including a therapeutically active agent, from about 0.1% to about 4.9% by weight of a pharmaceutically acceptable polymer, and from about 0.1% to about 30% by weight of a pharmaceutically acceptable acid, wherein the pharmaceutical composition have a zero order release profile of the therapeutically active agent. In another aspect, the invention provides methods for preparing and administering a pharmaceutical antibiotic composition in oral dosage form, such as a tablet.
Type:
Application
Filed:
June 3, 2003
Publication date:
December 9, 2004
Applicant:
BioKey, Inc.
Inventors:
Jenny Li-Ying Lin, David Wong, San-Laung Chow
Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, antiinflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.
Abstract: Most pain relief products on the market, if they work at all are labeled “for temporary relief”. A person in pain for whatever reason desires three things. Since pain is not enjoyable, quick action is the first. For the same reason, long lasting is the second. The third consideration is as safe a product as possible. “Pearl Blue” performs all these needs quite well. The lidocaine is quick, begins relief in some degree in minutes. The other 6 ingredients penetrate at different rates so that as one diminishes the others in succession are working down the time chart to bring their own individual relief for up to 3 hours or longer depending on the sufferers own body chemistry. And the ingredients work together to aid each other in the whole result and have been time tested individually to be safe for generations.
Type:
Application
Filed:
December 31, 2003
Publication date:
December 9, 2004
Inventors:
Charles Richard Le Roy, Deborah Gay Le Roy
Abstract: The present invention provides an immune modulator administration method whereby the modulators are formulated into a patch or cream to help patients in managing the diseases and alleviate the immune syndromes. The patch comprises a baking layer, a penetration enhancing layer, a carrier layer and a pressure sensitive adhesive layer. The application of immune modulators onto a topical patch or cream renders a method in the management of immune disorders either systemic or localized. The invention also provides clinicians a convenient mechanism for monitoring therapy responses. Furthermore, utilization of the present invention improves the quality of life for the living being to which the immune modulators are administrated. The concept and formulations of the present invention dramatically improve effectiveness of the treatment of autoimmune diseases such as psoriasis, rheumatoid arthritis, systematic lupus erythematosus, autoimmune hepatitis, hepatitis B and hepatitis C.
Abstract: A method is provided for treatment of an inflammatory condition in a fluid-containing organ having a natural exterior orifice, such as the udder of a milk producing animal or an ear. The method comprises administering, to the organ via the exterior orifice, a pharmaceutical composition comprising an anti-inflammatory agent and a vehicle that comprises an amphipathic oil that is water dispersible and ethanol insoluble, microcrystalline wax and a pharmaceutically acceptable non-aqueous carrier. Also provided is such a composition comprising the anti-inflammatory agent. The composition is readily dispersible in the fluid of the fluid-containing organ.
Type:
Application
Filed:
March 17, 2004
Publication date:
November 25, 2004
Inventors:
Nancy Jean Britten, Niki Ann Waldron, Jeffrey L. Watts, John Walter Hallberg, John W. Burns
Abstract: A pharmaceutical compsition is provided for treatment of conditions in mammals which are responsitive to COX-2 inhibition which comprises in combination a COX-2 inhibitor and low-dosa aspirin for simultaneous, sequential or separate use.
Abstract: The present invention relates to pharmaceutical compositions comprising a cathepsin K inhibitor which are useful for treating such conditions as bone resorption, osteoporosis, arthritis, tumor metastases, Paget's disease, and other metabolic bone disorders characterized by increased bone resorption.
Abstract: The present invention relates to inhibiting the production of TSST-1 using absorbent products and non-absorbent products comprising an additive, as well as methods for inhibiting such production. The absorbent and non-absorbent products or articles include an effective amount of an inhibitory compound, such as thiolactomycin or thiomalonate to substantially inhibit the production of TSST-1 or exoprotein by Gram positive bacteria.
Abstract: Methods and kits for regulating arterial microvascular tone in which a COX-2 inhibitor and a cannabinoid receptor agonist are co-administered to a subject.
Abstract: Provided are methods and compositions useful for treating disease and disorder associated with oxidative damage and the like. The methods and compositions are useful in the treatment of such disorders as Parkinson's disease. The compositions comprise an aqueous medium having dispersed or dissolved therein NAD (or a derivative thereof), glutathione (or a derivative thereof) and may further include an herbal therapeutic agent and/or an analgesic agent, wherein the composition is effective when delivered to the mucosal membrane.
Abstract: A composition and process for suppressing pain and irritation of tissue includes an anti-irritant in an effective amount to suppress pain and irritation temporarily when applied topically to the skin or mucosa. The anti-irritant is a natural or non-nutritive sweetener. The composition can be a solid containing an edible acid such as citric acid and ascorbic acid from fresh lemon juice to form a solution having a pH of about 2.0 to 4.0 and an anti-irritant, such as sodium saccharine. The composition can be used to apply a pharmaceutical agent to the skin, mucosa or eye without irritation. The acidic composition can further be used to remove or loosen calculus deposits from the teeth without burning or irritation of the gums.
Abstract: A pharmaceutical composition comprising a therapeutically effective amount of: (a) dipyridamole or a pharmaceutically acceptable salt thereof; (b) acetylsalicylic acid; and (c) an angiotensin II antagonist, kits containing these three compounds, and methods for preventing stroke or reducing the risk of stroke or secondary stroke in a patient in need thereof by administering an effective amount of these compounds to the patient.
Type:
Application
Filed:
February 3, 2004
Publication date:
October 28, 2004
Applicant:
Boehringer Ingelheim International GmbH
Inventors:
James C. Gilbert, Lutz Hilbrich, Axel Riedel, David Michael Humphreys
Abstract: The present invention relates to a method of treating or preventing pain and to pharmaceutical compositions useful for carrying out said methods. The present invention is directed to a method of treating or preventing pain comprising administering a selected analgesic and a beta adrenergic agonist to a subject in need of such treatment, wherein said beta adrenergic agonist produces an enhanced effect of said analgesic. The present invention is also directed to pharmaceutical compositions comprising an analgesic and a beta adrenergic agonist useful for carrying out the method of the present invention.
Abstract: This invention relates to the use of combinations of a sodium channel blocking compound that binds to an SSI or SS2 site of extracellular region of a sodium channel alpha subunit, and aspirin in manufacturing drugs for producing synergistically analgesic effect in mammals. Pharmaceutical compositions based upon this invention can enhance analgesic effect and reduce dosage of aspirin, therefore side effects and adverse reactions are decreased accordingly.
Abstract: A medicament for the amelioration and treatment of vascular disease consisting of aspirin administered in combination with one or more of the vitamins including vitamin A, vitamin B6, vitamin C, vitamin E, and niacin. Alternative embodiments include the administration of aspirin in combination with one or more trace element including selenium, zinc, copper, iron, cobalt, and manganese as well as combinations of aspirin, at least one vitamin and at least one trace element.
Abstract: The present disclosure relates to novel cocrystals and novel methods for cocrystallization. In particular, the disclosure includes cocrystals comprising a salt of an active agent, such as a chloride salt of an active pharmaceutical ingredient. The present disclosure also relates to methods of preparing cocrystals and methods for screening for solid state phases.
Abstract: This invention relates to treating an inflammatory disease by administering a phosphodiesterase 4 inhibitor in combination with an inhibitor of prostaglandin synthesis, NSAIDs being exemplary.